The Cross-sectional GRAS Sample: a Comprehensive Phenotypical Data Collection of Schizophrenic Patients

Background: Schizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of mental disorders with still obscure biological roots. Based on the assumption that valuable information about relevant genetic and environmental disease mechanisms can be obtained by association studies on patient cohorts of ≥ 1000 patients, if performed on detailed clinical datasets and quantifiable biological readouts, we generated a new schizophrenia data base, the GRAS (Göttingen Research Association for Schizophrenia) data collection. GRAS is the necessary ground to study genetic causes of the schizophrenic phenotype in a 'phenotype-based genetic association study' (PGAS). This approach is different from and complementary to the genome-wide association studies (GWAS) on schizophrenia.

Methods: For this purpose, 1085 patients were recruited between 2005 and 2010 by an invariable team of traveling investigators in a cross-sectional field study that comprised 23 German psychiatric hospitals. Additionally, chart records and discharge letters of all patients were collected.

Results: The corresponding dataset extracted and presented in form of an overview here, comprises biographic information, disease history, medication including side effects, and results of comprehensive cross-sectional psychopathological, neuropsychological, and neurological examinations. With >3000 data points per schizophrenic subject, this data base of living patients, who are also accessible for follow-up studies, provides a wide-ranging and standardized phenotype characterization of as yet unprecedented detail.

Conclusions: The GRAS data base will serve as prerequisite for PGAS, a novel approach to better understanding 'the schizophrenias' through exploring the contribution of genetic variation to the schizophrenic phenotypes.

Citing Articles

Study protocol of the Berlin Research Initiative for Diagnostics, Genetics and Environmental Factors in Schizophrenia (BRIDGE-S).

Braun A, Kraft J, Ripke S BMC Psychiatry. 2023; 23(1):31.

PMID: 36635663 PMC: 9835268. DOI: 10.1186/s12888-022-04447-4.

Assessment and correlates of autistic symptoms in Schizophrenia Spectrum Disorders measured with the PANSS Autism Severity Score: A systematic review.

Nibbio G, Barlati S, Calzavara-Pinton I, Necchini N, Invernizzi E, DellOvo D Front Psychiatry. 2022; 13:934005.

PMID: 36111306 PMC: 9468543. DOI: 10.3389/fpsyt.2022.934005.

Human genomics of the humoral immune response against polyomaviruses.

Hodel F, Chong A, Scepanovic P, Xu Z, Naret O, Thorball C Virus Evol. 2021; 7(2):veab058.

PMID: 34532061 PMC: 8438875. DOI: 10.1093/ve/veab058.

Preadult polytoxicomania-strong environmental underpinnings and first genetic hints.

Steixner-Kumar A, Daguano Gastaldi V, Seidel J, Rosenberger A, Begemann M, Ehrenreich H Mol Psychiatry. 2021; 26(7):3211-3222.

PMID: 33824432 PMC: 8505259. DOI: 10.1038/s41380-021-01069-2.

Hippocampal neurons respond to brain activity with functional hypoxia.

Butt U, Steixner-Kumar A, Depp C, Sun T, Hassouna I, Wustefeld L Mol Psychiatry. 2021; 26(6):1790-1807.

PMID: 33564132 PMC: 8440186. DOI: 10.1038/s41380-020-00988-w.

References

Lehrl S, Triebig G, Fischer B . Multiple choice vocabulary test MWT as a valid and short test to estimate premorbid intelligence. Acta Neurol Scand. 1995; 91(5):335-45. DOI: 10.1111/j.1600-0404.1995.tb07018.x. View

Weiser M, Reichenberg A, Rabinowitz J, Kaplan Z, Mark M, Nahon D . Gender differences in premorbid cognitive performance in a national cohort of schizophrenic patients. Schizophr Res. 2000; 45(3):185-90. DOI: 10.1016/s0920-9964(99)00190-5. View

Moriarty P, Lieber D, Bennett A, White L, Parrella M, Harvey P . Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr Bull. 2001; 27(1):103-13. DOI: 10.1093/oxfordjournals.schbul.a006850. View

Price G, Michie P, Johnston J, Innes-Brown H, Kent A, Clissa P . A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia. Biol Psychiatry. 2005; 60(1):1-10. DOI: 10.1016/j.biopsych.2005.09.010. View

Fleischhacker W, Keet I, Kahn R . The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005; 78(2-3):147-56. DOI: 10.1016/j.schres.2005.06.004. View

Franzek E, Beckmann H . Different genetic background of schizophrenia spectrum psychoses: a twin study. Am J Psychiatry. 1998; 155(1):76-83. DOI: 10.1176/ajp.155.1.76. View

Gaite L, Vazquez-Barquero J, Herran A, Thornicroft G, Becker T, Sierra-Biddle D . Main determinants of Global Assessment of Functioning score in schizophrenia: a European multicenter study. Compr Psychiatry. 2005; 46(6):440-6. DOI: 10.1016/j.comppsych.2005.03.006. View

Pinheiro A, Keefe R, Skelly T, Olarte M, Leviel K, Lange L . AKT1 and neurocognition in schizophrenia. Aust N Z J Psychiatry. 2007; 41(2):169-77. DOI: 10.1080/00048670601109956. View

Cardno A, Gottesman I . Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet. 2000; 97(1):12-7. View

10.

Sullivan P, Keefe R, Lange L, Lange E, Stroup T, Lieberman J . NCAM1 and neurocognition in schizophrenia. Biol Psychiatry. 2006; 61(7):902-10. DOI: 10.1016/j.biopsych.2006.07.036. View

11.

Kern R, Nuechterlein K, Green M, Baade L, Fenton W, Gold J . The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008; 165(2):214-20. DOI: 10.1176/appi.ajp.2007.07010043. View

12.

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

13.

Riecher-Rossler A, Hafner H . Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl. 2001; (407):58-62. DOI: 10.1034/j.1600-0447.2000.00011.x. View

14.

McGrath J, Saha S, Chant D, Welham J . Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008; 30:67-76. DOI: 10.1093/epirev/mxn001. View

15.

Loughland C, Carr V, Lewin T . The NISAD Schizophrenia Research Register: why do we need a database of schizophrenia volunteers?. Aust N Z J Psychiatry. 2001; 35(5):660-7. DOI: 10.1080/0004867010060516. View

16.

Chen E, Shapleske J, Luque R, McKenna P, Hodges J, Calloway S . The Cambridge Neurological Inventory: a clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res. 1995; 56(2):183-204. DOI: 10.1016/0165-1781(95)02535-2. View

17.

Hafner H, Maurer K, Loffler W, An der Heiden W, Munk-Jorgensen P, Hambrecht M . The ABC Schizophrenia Study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol. 1998; 33(8):380-6. DOI: 10.1007/s001270050069. View

18.

Simpson G, Lee J, Zoubok B, Gardos G . A rating scale for tardive dyskinesia. Psychopharmacology (Berl). 1979; 64(2):171-9. DOI: 10.1007/BF00496058. View

19.

Toro P, Bellavia C, Daeschler C, Owens B, Wall D, Passero J . Distinguishing homelessness from poverty: a comparative study. J Consult Clin Psychol. 1995; 63(2):280-9. DOI: 10.1037//0022-006x.63.2.280. View

20.

Sullivan P, Lin D, Tzeng J, van den Oord E, Perkins D, Stroup T . Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry. 2008; 13(6):570-84. PMC: 3910086. DOI: 10.1038/mp.2008.25. View